Revenio Group (REG1V) Status update summary

Strategic update and market positioning

• Expanded product portfolio and market reach through the Visionix acquisition, now covering a broader range of ophthalmic diagnostic and treatment devices, including OCT and lens finishing equipment.

• Addressing strong global megatrends such as aging populations, rising lifestyle diseases, and technological advancements, which drive demand for eye care solutions.

• Enhanced direct market presence in key regions, leveraging combined distribution networks and commercial strengths for greater market impact.

• Focus on scalable, efficient go-to-market models and maximizing cross-selling opportunities across expanded customer segments.

• Strategic goal for 2027-2029 is to lead the shift from vision care to comprehensive eye health, emphasizing clinical certainty, workflow efficiency, and sustainable growth.

Financial performance and targets

• Pro forma revenue for 2025 estimated at €252.8 million, with a pro forma adjusted EBITDA of €45.3 million.

• Targeting 5-10% average annual organic revenue growth for 2027-2029 and an adjusted EBITDA margin of 25% by the end of 2029.

• Over €20 million in EBITDA growth expected by 2029 from synergies and value creation post-Visionix transaction, with 70% of synergies anticipated by 2027.

• Key drivers for growth include portfolio expansion, cross-selling, geographic reach, and innovation in integrated solutions.

• Margin improvement to be driven by synergies, operational scalability, and increased share of higher-margin services and software.

Rights issue details

• Rights issue aims to raise approximately €80 million gross to refinance bridge financing from the Visionix acquisition and ensure a balanced capital structure.

• Up to 12,929,361 new shares offered at €6.19 per share, with a subscription ratio of 4 new shares for every 9 existing shares.

• Subscription period runs from 28 September to 12 October 2026, with trading in rights from 28 September to 6 October 2026.

• Major shareholders and Visionix sellers have committed to subscribe for about 31.4% of the offered shares; Nordea provides underwriting for the remainder.

• Investors can use, buy, or sell rights, or subscribe for shares without rights in a secondary subscription.